Certus Laboratories, LLC

Certus Laboratories, LLC was paid $1.96M by Medicaid between Jan 2018 and Dec 2024, across 30 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 34% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Mississippi

Rank by total paid#5 of 35

Median peer was paid$136K

This provider vs. median14×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,559	$217K
2019	5,109	$229K
2020	2,549	$222K
2021	3,440	$302K
2022	2,483	$248K
2023	2,989	$257K
2024incomplete	14,923	$488K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	34%	5,894	5,031	$672K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	29%	7,914	6,341	$575K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	13%	8,221	6,507	$252K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	7.0%	1,959	1,464	$138K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.2%	1,825	1,616	$122K
87481		2.1%	1,105	917	$42K
87631		1.4%	540	475	$27K
87500		<1%	1,103	978	$13K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	38	28	$13K
87641		<1%	1,098	977	$13K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	189	120	$12K
87640		<1%	1,146	955	$10K

18 more codes

87529		<1%	483	$10K
87653		<1%	1,012	$9K
87581		<1%	597	$9K
87541		<1%	586	$8K
87486		<1%	559	$7K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	483	$6K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	483	$6K
87511		<1%	476	$5K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	189	$4K
87563		<1%	325	$3K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	168	$3K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	325	$2K
87498		<1%	30	$731.26
87505		<1%	25	$359.21
36415	Collection of venous blood by venipuncture	<1%	131	$138.61
80053	Comprehensive metabolic panel	<1%	72	$47.50
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	59	$13.98
83036	Hemoglobin; glycosylated (A1C)	<1%	17	$7.77

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBLACKWELL, JUSTIN (MANAGING MEMBER)